Tatsumi Kagaku Co., Ltd.
Japanese generic pharmaceutical manufacturer based in Kanazawa, Ishikawa, producing oral solid, antibiotic, injection and ointment formulations.
Last updated September 27, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Tatsumi Kagaku Co., Ltd. (辰巳化学株式会社) is a Japanese pharmaceutical company headquartered in Kanazawa, Ishikawa Prefecture, that manufactures and sells generic prescription medicines. The company was founded in July 1941 (Showa 16) in Kamikurumicho, Kanazawa, with initial capital of 180,000 yen, and has since grown into a mid-sized generic drug maker with its own manufacturing and research infrastructure in Ishikawa Prefecture. Tatsumi Kagaku's core business is the development, manufacture and sale of generic pharmaceuticals in Japan. Its product range has historically covered oral solid preparations, antibiotics, injections, ointments and oral liquids, supported by successive plant expansions in the Matsuto (now Hakusan) area. The company operates a first research laboratory in Fukudome-cho, Hakusan, and production facilities including the Matsuto No. 1 Plant, where it has added GMP-compliant formulation buildings over the years. As a generic manufacturer, Tatsumi Kagaku positions itself around stable supply, quality assurance and information provision to medical institutions and healthcare professionals. It is a member of the Japan Generic Medicines Association (JGA / GE薬協) and follows that association's corporate action charter, compliance program guidelines and code of practice. The company publishes a transparency guideline on relationships between its corporate activities and medical institutions, disclosing funding such as research and development expenses, academic research grants, and manuscript fees on its website. The company's public communications include a virtual factory tour, explanatory content about generic medicines, and a corporate introduction TV commercial. Its history page records a long series of capital increases, plant constructions and relocations, culminating in reaching its 100th fiscal term in July 2025. Tatsumi Kagaku remains a privately held Japanese company focused on the domestic generic drug market.
History
Tatsumi Kagaku Co., Ltd. was founded in July 1941 (Showa 16) in Kamikurumicho, Kanazawa, Ishikawa Prefecture, with capital of 180,000 yen. In June 1949 (Showa 24), a capital increase brought capital to 1,200,000 yen. In June 1959 (Showa 34), the head office and head office plant were newly built and relocated to Kasamachi, Kanazawa. During the 1960s the company expanded its capital repeatedly: to 5,400,000 yen in January 1966 (Showa 41), to 29,180,000 yen in August 1967 (Showa 42) through a public offering of shares, and to 34,330,000 yen in April 1968 (Showa 43) alongside an expansion of the head office plant. In November 1970 (Showa 45), laboratories and production facilities were expanded and capital reached 84,000,000 yen. In May 1973 (Showa 48), a new head office was established in Mima-cho, Kanazawa. In September 1973, the first phase of the Matsuto No. 1 Plant, a sugar-coating plant, was built in Kamiyasuda-cho, Matsuto City. In August 1974 (Showa 49), a second-phase oral solid formulation plant was added at Matsuto No. 1 Plant, and capital rose to 134,000,000 yen with participation from Nagoya Small and Medium Business Investment & Consultation Co., Ltd. In July 1975 (Showa 50), Tatsumi Kagaku Sales Co., Ltd. was absorbed through merger, bringing capital to 174,000,000 yen. In August 1976 (Showa 51), a third-phase antibiotic formulation plant was added at Matsuto No. 1 Plant. In July 1979 (Showa 54), the head office moved to Mima 3-chome, Kanazawa. In August 1979, a fourth-phase expansion at Matsuto No. 1 Plant added a testing laboratory, injection and ointment facilities, oral liquid facilities and a materials warehouse, and the head office plant was fully relocated there. In July 1984 (Showa 59), the First Research Laboratory was established in Fukudome-cho, Hakusan City (formerly Matsuto City). In October 1995 (Heisei 7), Matsuto No. 1 Plant was extended with a new GMP-compliant formulation building (G Building) and production equipment was expanded. In October 1998 (Heisei 10), the head office moved to Kyuyasu 3-chome, Kanazawa. In April 2007 (Heisei 19), a new solid formulation building (M Building) was added at Matsuto No. 1 Plant to meet GMP standards and expand production scale. In July 2010 (Heisei 22), a shipping center was built in Hakusan City, Ishikawa Prefecture. In July 2015 (Heisei 27), a quality control and welfare building was newly constructed to further strengthen the quality management system. In December 2015, an oral solid formulation building (P Building) compliant with global tri-polar GMP and PIC/S was added to respond to growing demand. In November 2020 (Reiwa 2), G Building was extended to further improve production capacity. In July 2025 (Reiwa 7), the company reached its 100th fiscal term since founding.
- 2025
Reached the 100th fiscal term since founding.
- 2020
G Building extended to further improve production capacity.
- 2015
Quality control and welfare building newly constructed; oral solid formulation building (P Building) compliant with global tri-polar GMP and PIC/S added.
- 2010
Shipping center built in Hakusan City, Ishikawa Prefecture.
- 2007
New solid formulation building (M Building) added at Matsuto No. 1 Plant to meet GMP standards and expand production scale.
- 1998
Head office moved to Kyuyasu 3-chome, Kanazawa.
- 1995
Matsuto No. 1 Plant extended with new GMP-compliant formulation building (G Building).
- 1984
First Research Laboratory established in Fukudome-cho, Hakusan City (formerly Matsuto City).
- 1979
Head office moved to Mima 3-chome, Kanazawa; fourth-phase expansion at Matsuto No. 1 Plant added testing laboratory, injection/ointment, oral liquid and warehouse facilities, and head office plant fully relocated.
- 1976
Third-phase antibiotic formulation plant added at Matsuto No. 1 Plant.
Products and positioning
Japanese generic pharmaceutical manufacturer emphasizing stable supply, quality assurance and transparency toward medical institutions.
Generic prescription medicines
The company's core line of generic pharmaceuticals manufactured and sold in Japan.
Oral solid formulations
Produced at GMP-compliant facilities including the M Building and P Building.
Antibiotic formulations
Antibiotic production capacity added at Matsuto No. 1 Plant in 1976.
Injections and ointments
Facilities for injections and ointments were added in the 1979 expansion.
Oral liquid formulations
Oral liquid production facilities were added in the 1979 expansion.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/tatsumi-kagaku-co-ltd-japan · Editorial policy · How profiles are compiled